SCHEMBL31358734

SCHEMBL31358734

O=C1C(=Cc2ccc(-c3cccc4ccccc34)o2)Sc2ccccc21

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN5 P54829 2/20 0.54
PTPN1 P18031 1/20 0.54
PTPN7 P35236 1/20 0.54
DUSP3 P51452 1/20 0.54
PTPN22 Q9Y2R2 1/20 0.54
CYP1A2 P05177 2/20 0.47
MAPT P10636 6/20 0.45
MEN1 O00255 4/20 0.45
KMT2A Q03164 4/20 0.45
SMN1; SMN2 Q16637 3/20 0.45
RAB9A P51151 2/20 0.45
MAPK1 P28482 2/20 0.45
CASP3 P42574 1/20 0.45
SENP8 Q96LD8 1/20 0.45
SENP7 Q9BQF6 1/20 0.45
SENP6 Q9GZR1 1/20 0.45
PIK3CG P48736 4/20 0.44
PIK3CA P42336 1/20 0.44
PIK3CB P42338 1/20 0.44
POLB P06746 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31358770 0.82 PTPN5 (0.64) PTPN5PTPN1PTPN7DUSP3PTPN22
SCHEMBL25246954 0.82 PTPN5 (0.68) PTPN5PTPN1PTPN7DUSP3PTPN22
SCHEMBL31358848 0.82 PTPN5 (0.68) PTPN5PTPN1PTPN7DUSP3PTPN22
SCHEMBL31358679 0.81 IGF1R (0.64) PTPN5PTPN1PTPN7DUSP3PTPN22
SCHEMBL31358703 0.81 PTPN5 (0.64) PTPN5PTPN1PTPN7DUSP3PTPN22
SCHEMBL31358836 0.80 PTPN5 (0.59) PTPN5PTPN1PTPN7DUSP3PTPN22
SCHEMBL31358846 0.79 TNFRSF1A (0.58) PTPN5PTPN1PTPN7DUSP3PTPN22
SCHEMBL31358674 0.79 BRAF (0.55) PTPN5PTPN1PTPN7DUSP3PTPN22
SCHEMBL31358738 0.79 TNFRSF1A (0.58) PTPN5PTPN1PTPN7DUSP3PTPN22
SCHEMBL25218896 0.78 PTPN5 (0.69) PTPN5PTPN1PTPN7DUSP3PTPN22

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250026741-A1 INHIBITORS OF THE ONCOGENIC SHP2 PHOSPHATASE AND USES THEREOF Sanford Burnham Prebys Medical Discovery Institute 2025-01-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250026741-A1 INHIBITORS OF THE ONCOGENIC SHP2 PHOSPHATASE AND USES THEREOF PTPN18, PTPN7, PTPN1 PTPN5 8/4885PTPN1 3/4885PTPN7 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.